GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Asset Turnover

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Asset Turnover : 0.11 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Amphastar Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $171.8 Mil. Amphastar Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was $1,543.6 Mil. Therefore, Amphastar Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.11.

Asset Turnover is linked to ROE % through Du Pont Formula. Amphastar Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2024 was 26.33%. It is also linked to ROA % through Du Pont Formula. Amphastar Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was 11.19%.


Amphastar Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Amphastar Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Asset Turnover Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.57 0.67 0.71 0.57

Amphastar Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.14 0.12 0.12 0.11

Competitive Comparison of Amphastar Pharmaceuticals's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Asset Turnover falls into.



Amphastar Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Amphastar Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=644.395/( (741.987+1512.912)/ 2 )
=644.395/1127.4495
=0.57

Amphastar Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=171.836/( (1512.912+1574.317)/ 2 )
=171.836/1543.6145
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Amphastar Pharmaceuticals  (NAS:AMPH) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Amphastar Pharmaceuticals's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=172.708/655.8885
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(172.708 / 687.344)*(687.344 / 1543.6145)*(1543.6145/ 655.8885)
=Net Margin %*Asset Turnover*Equity Multiplier
=25.13 %*0.4453*2.3535
=ROA %*Equity Multiplier
=11.19 %*2.3535
=26.33 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Amphastar Pharmaceuticals's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=172.708/1543.6145
=(Net Income / Revenue)*(Revenue / Total Assets)
=(172.708 / 687.344)*(687.344 / 1543.6145)
=Net Margin %*Asset Turnover
=25.13 %*0.4453
=11.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Amphastar Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Executives
Mary Z. Luo director, 10 percent owner, officer: COO and Chief Scientist 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou officer: EVP, Production C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins director
William J Peters officer: CFO, SVP & Treasurer C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi officer: SVP Corp Admin Center C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff director
Gayle Deflin director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst officer: EVP, QA & Regulatory Affairs 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee director 13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang director, 10 percent owner, officer: CEO & Chief Scientific Officer 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris director C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo director 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell director, officer: President 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc. 10 percent owner 13760 MAGNOLIA AVENUE, CHINO CA 91710